{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:02:24Z","timestamp":1790758944981,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, yet the contribution of autonomic dysfunction to its progression remains incompletely understood. Pheochromocytoma and paraganglioma (PPGL), characterized by excessive catecholamine production, provide a human model to investigate the impact of chronic sympathetic activation on MASLD and major adverse liver outcomes (MALO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using data from the TriNetX Network, including adults with PPGL (exposure) and essential hypertension (controls), defined using ICD-10 codes\/anthropometry. Cohorts were propensity score matched (1:1) for demographic, metabolic, and blood pressure\u2013related variables and followed for 5 years from index diagnosis. The primary outcome was time to incident MASLD. Secondary outcomes included MALO, type 2 diabetes (T2D), major adverse cardiovascular events (MACE), and all-cause mortality. Survival analysis generated hazard ratios (HR) and 95% confidence intervals (95% CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, 45 595 patients were included in each arm. PPGL was associated with increased risk of incident MASLD (HR 1.48; 95% CI 1.38\u20131.58) and MALO (HR 1.59; 1.44-1.76), including hepatic decompensation (HR 1.73; 1.53-1.95) and hepatocellular carcinoma (HR 2.18; 1.70-2.80), compared with essential hypertension. A modest increase in MACE was observed (HR 1.13; 1.09-1.16), while incident T2D risk was not significantly different (HR 1.02; 0.98-1.06). Pheochromocytoma and PPGL treated with \u03b1-adrenergic blockade demonstrated greatest cardiometabolic risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PPGL was associated with increased risk of MASLD, progressive liver complications, MACE, and mortality, supporting a link between chronic catecholamine excess and adverse hepatic outcomes. These findings provide human evidence that sustained sympathetic overactivity may contribute to hepatic steatosis and progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag176","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:52:55Z","timestamp":1789624375000},"page":"529-539","source":"Crossref","is-referenced-by-count":0,"title":["Increased risk of steatotic liver disease, major adverse liver outcomes, cardiovascular events, and mortality in pheochromocytoma: a model of chronically elevated sympathetic tone"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8066-9470","authenticated-orcid":false,"given":"Alex E","family":"Henney","sequence":"first","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, University of Liverpool , Liverpool L69 7ZX ,","place":["United Kingdom"]},{"name":"Metabolism and Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust , Liverpool, Merseyside L9 7AL ,","place":["United Kingdom"]},{"name":"Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust , Liverpool, Merseyside L14 3PE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-4475","authenticated-orcid":false,"given":"Andrew S","family":"Davison","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust , Liverpool, Merseyside L7 8XP ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, University of Liverpool , Liverpool L69 7ZX ,","place":["United Kingdom"]},{"name":"Metabolism and Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust , Liverpool, Merseyside L9 7AL ,","place":["United Kingdom"]},{"name":"Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust , Liverpool, Merseyside L14 3PE ,","place":["United Kingdom"]},{"name":"Centre for Biomechanics and Rehabilitation Technologies, Staffordshire University , Stoke-on-Trent ST4 2DF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Cuthbertson","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, University of Liverpool , Liverpool L69 7ZX ,","place":["United Kingdom"]},{"name":"Metabolism and Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust , Liverpool, Merseyside L9 7AL ,","place":["United Kingdom"]},{"name":"Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust , Liverpool, Merseyside L14 3PE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"2","key":"2026093004252311300_lvag176-B1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease in adults: a review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"issue":"4","key":"2026093004252311300_lvag176-B2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"12","key":"2026093004252311300_lvag176-B3","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1111\/jdi.13691","article-title":"Autonomic dysfunction, diabetes and metabolic syndrome","volume":"12","author":"Yu","year":"2021","journal-title":"J Diabetes Investig"},{"key":"2026093004252311300_lvag176-B4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fmed.2020.00062","article-title":"Hepatic autonomic nervous system and neurotrophic factors regulate the pathogenesis and progression of non-alcoholic fatty liver disease","volume":"7","author":"Amir","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"2026093004252311300_lvag176-B5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.bbadis.2010.01.006","article-title":"The role of the autonomic nervous liver innervation in the control of energy metabolism","volume":"1802","author":"Yi","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"17","key":"2026093004252311300_lvag176-B6","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1113\/JP277994","article-title":"Liver sympathetic denervation reverses obesity-induced hepatic steatosis","volume":"597","author":"Hurr","year":"2019","journal-title":"J Physiol"},{"issue":"11","key":"2026093004252311300_lvag176-B7","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.2337\/db16-0698","article-title":"Renal denervation reverses hepatic insulin resistance induced by high-fat diet","volume":"65","author":"Iyer","year":"2016","journal-title":"Diabetes"},{"issue":"4","key":"2026093004252311300_lvag176-B8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1161\/HYPERTENSIONAHA.114.04798","article-title":"Denervation of the renal arteries in metabolic syndrome","volume":"65","author":"Verloop","year":"2015","journal-title":"Hypertension"},{"key":"2026093004252311300_lvag176-B9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fphys.2017.00369","article-title":"The effect of renal denervation on plasma adipokine profile in patients with treatment resistant hypertension","volume":"8","author":"Eikelis","year":"2017","journal-title":"Front Physiol"},{"issue":"4","key":"2026093004252311300_lvag176-B10","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.clnu.2021.02.027","article-title":"Metabolic effects two years after renal denervation in insulin resistant hypertensive patients. The Re-Shape CV-risk study","volume":"40","author":"Miroslawska","year":"2021","journal-title":"Clin Nutr"},{"issue":"7","key":"2026093004252311300_lvag176-B11","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf184","article-title":"Effect of renal denervation on glucose metabolism in hypertensive patients with and without chronic kidney disease","volume":"18","author":"Bytyqi","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026093004252311300_lvag176-B12","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6915310","article-title":"Effects of renal denervation on insulin sensitivity and inflammatory markers in nondiabetic patients with treatment-resistant hypertension","volume":"2017","author":"Kampmann","year":"2017","journal-title":"J Diabetes Res"},{"issue":"18","key":"2026093004252311300_lvag176-B13","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1161\/CIRCULATIONAHA.110.991869","article-title":"Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study","volume":"123","author":"Mahfoud","year":"2011","journal-title":"Circulation"},{"key":"2026093004252311300_lvag176-B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1433582","article-title":"Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment","volume":"15","author":"Saavedra","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026093004252311300_lvag176-B15","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1210\/endrev\/bnad011","article-title":"Biochemical assessment of pheochromocytoma and paraganglioma","volume":"44","author":"Eisenhofer","year":"2023","journal-title":"Endocr Rev"},{"issue":"3","key":"2026093004252311300_lvag176-B16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1161\/HYPERTENSIONAHA.123.21902","article-title":"Cardiovascular complications in pheochromocytoma and paraganglioma: does phenotype matter?","volume":"81","author":"Petr\u00e1k","year":"2024","journal-title":"Hypertension"},{"issue":"8","key":"2026093004252311300_lvag176-B17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4158\/EP171914.RA","article-title":"The physiology behind diabetes mellitus in patients with pheochromocytoma: a review of the literature","volume":"23","author":"Mesmar","year":"2017","journal-title":"Endocr Pract"},{"issue":"6","key":"2026093004252311300_lvag176-B18","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.dsx.2020.10.030","article-title":"Diabetes mellitus in pheochromocytoma and paraganglioma: prevalence, dynamics of insulin secretion\/sensitivity and predictors of remission","volume":"14","author":"Khatiwada","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"2026093004252311300_lvag176-B19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s12020-023-03492-7","article-title":"Secondary diabetes mellitus in pheochromocytomas and paragangliomas","volume":"82","author":"Moustaki","year":"2023","journal-title":"Endocrine"},{"issue":"8","key":"2026093004252311300_lvag176-B20","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1210\/jc.2003-030000","article-title":"Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma","volume":"88","author":"Wiesner","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026093004252311300_lvag176-B21","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"4","key":"2026093004252311300_lvag176-B22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"7624","key":"2026093004252311300_lvag176-B23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Elm","year":"2007","journal-title":"BMJ"},{"issue":"11","key":"2026093004252311300_lvag176-B24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11906-019-0989-9","article-title":"Pheochromocytoma as a clinical model of peripheral sympathetic overdrive: old and new findings","volume":"21","author":"Grassi","year":"2019","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"2026093004252311300_lvag176-B25","doi-asserted-by":"publisher","first-page":"E107","DOI":"10.1152\/ajpendo.00205.2023","article-title":"Human liver afferent and efferent nerves revealed by 3-D\/Airyscan super-resolution imaging","volume":"326","author":"Chen","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026093004252311300_lvag176-B26","doi-asserted-by":"publisher","first-page":"752944","DOI":"10.3389\/fendo.2021.752944","article-title":"Autonomic imbalance increases the risk for non-alcoholic fatty liver disease","volume":"12","author":"Jung","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026093004252311300_lvag176-B27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/cells11061021","article-title":"The role of catecholamines in pathophysiological liver processes","volume":"11","author":"Lelou","year":"2022","journal-title":"Cells"},{"issue":"3","key":"2026093004252311300_lvag176-B28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/cen.15181","article-title":"Long-term cardiovascular complications in patients with pheochromocytomas and paragangliomas after surgery: a large multi-center study","volume":"102","author":"Guo","year":"2025","journal-title":"Clin Endocrinol"},{"issue":"5","key":"2026093004252311300_lvag176-B29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/CRD.0000000000000141","article-title":"Cardiovascular manifestations of pheochromocytoma","volume":"25","author":"Gu","year":"2017","journal-title":"Cardiol Rev"},{"issue":"12","key":"2026093004252311300_lvag176-B30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/ERC-22-0218","article-title":"Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas","volume":"29","author":"Araujo-Castro","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026093004252311300_lvag176-B31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/aam.aam_13_20","article-title":"Pheochromocytoma and glucoregulation disorders","volume":"20","author":"Derrou","year":"2021","journal-title":"Ann Afr Med"},{"issue":"3","key":"2026093004252311300_lvag176-B32","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/dom.70347","article-title":"Chronically elevated sympathetic nervous system tone: a significant, common, and poorly realised contributor to cardiometabolic disease in type 2 diabetes","volume":"28","author":"DeFronzo","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2026093004252311300_lvag176-B33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1172\/JCI109718","article-title":"Epinephrine-induced insulin resistance in man","volume":"65","author":"Deibert","year":"1980","journal-title":"J Clin Invest"},{"key":"2026093004252311300_lvag176-B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103489","article-title":"Spinal cord stimulation for the treatment of painful diabetic neuropathy and risk of major adverse cardiovascular events, mortality, amputation, infection and suicide: a retrospective cohort study","volume":"89","author":"Henney","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"9145","key":"2026093004252311300_lvag176-B35","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/S0140-6736(98)02478-7","article-title":"Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial","volume":"352","author":"Malik","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"2026093004252311300_lvag176-B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189141","article-title":"Clinical and molecular markers guide the genetics of pheochromocytoma and paraganglioma","volume":"1879","author":"Casc\u00f3n","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag176\/71168315\/lvag176.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/3\/529\/71168315\/lvag176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/3\/529\/71168315\/lvag176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:25:59Z","timestamp":1790756759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/195\/3\/529\/8808956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag176","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,28]]}}}